Literature DB >> 11832703

Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.

H Ballentine Carter1, Patrick C Walsh, Patricia Landis, Jonathan I Epstein.   

Abstract

PURPOSE: We evaluate a strategy of expectant management for men with stage T1c prostate cancer.
MATERIALS AND METHODS: A total of 81 men (median age 65 years, range 52 to 72) with stage T1c prostate cancer who were thought to have small volume prostate cancer based on needle biopsy findings and prostate specific antigen (PSA) density were followed for more than 1 year with semiannual PSA and digital rectal examination, and annual prostate biopsies (median followup 23 months, range 12 to 58). A recommendation for treatment was made if disease progression was indicated by unfavorable followup needle biopsy findings (Gleason pattern 4 or 5, greater than 2 biopsy cores with cancer, greater than 50% involvement of any core with cancer). Curable disease was defined on pathological examination of radical prostatectomy specimens as 1) organ confined cancer of Gleason score 7 or less, 2) cancer with extraprostatic extension of Gleason score 7 (3+4) or less with negative margins, seminal vesicles and lymph nodes, or 3) cancer of Gleason score 6 or less regardless of margin status or extraprostatic extension if negative seminal vesicles and lymph nodes.
RESULTS: Of the 81 men 25 (31%) had progression of disease at followup. PSA density was statistically significantly higher (p = 0.01) and the percentage of free PSA was statistically significantly lower (p = 0.04) in men with compared to those without disease progression. Disease progression occurred in 22 of 39 men (56%) with every followup biopsy showing cancer compared to 3 of 42 (2%) men with 1 or more negative followup biopsies (p <0.001). Of the 25 men with progression 13 underwent radical prostatectomy and 12 of 13 (92%) had curable cancers.
CONCLUSIONS: Expectant management with curative intent may be a reasonable alternative for carefully selected older men who are thought to have small volume cancers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11832703

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  51 in total

Review 1.  Active surveillance for low-risk prostate cancer: an update.

Authors:  Nathan Lawrentschuk; Laurence Klotz
Journal:  Nat Rev Urol       Date:  2011-04-26       Impact factor: 14.432

Review 2.  Molecular profiling of indolent human prostate cancer: tackling technical challenges to achieve high-fidelity genome-wide data.

Authors:  Thomas A Dunn; Helen L Fedor; Angelo M De Marzo; Jun Luo
Journal:  Asian J Androl       Date:  2012-02-06       Impact factor: 3.285

3.  Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial.

Authors:  Stephen B Williams; Simpa Salami; Meredith M Regan; Donna P Ankerst; John T Wei; Mark A Rubin; Ian M Thompson; Martin G Sanda
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

4.  Expectant management of prostate cancer.

Authors:  Masood A Khan; Alan W Partin
Journal:  Rev Urol       Date:  2003

5.  Best of the 2007 AUA Annual Meeting: Highlights from the 2007 Annual Meeting of the American Urological Association, May 19-24, 2007, Anaheim, CA.

Authors:  Michael K Brawer; Danil V Makarov; Alan W Partin; Claus G Roehrborn; J Curtis Nickel; Michael B Chancellor; Dean G Assimos; Ellen Shapiro; Jacob Rajfer
Journal:  Rev Urol       Date:  2007

6.  Best of the 2008 AUA Annual Meeting: Highlights from the 2008 Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FL.

Authors:  Michael K Brawer; Danil V Makarov; Alan W Partin; Claus G Roehrborn; J Curtis Nickel; Shing-Hwa Lu; Naoki Yoshimura; Michael B Chancellor; Dean G Assimos
Journal:  Rev Urol       Date:  2008

7.  Low-risk prostate cancer and low testosterone: what are the acceptable alternatives?

Authors:  Mark Soloway
Journal:  Curr Urol Rep       Date:  2009-11       Impact factor: 3.092

8.  Vascular targeted photodynamic therapy for localized prostate cancer.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2008

Review 9.  Active surveillance for prostate cancer: current evidence and contemporary state of practice.

Authors:  Jeffrey J Tosoian; H Ballentine Carter; Abbey Lepor; Stacy Loeb
Journal:  Nat Rev Urol       Date:  2016-03-08       Impact factor: 14.432

10.  Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

Authors:  Jeffrey J Tosoian; Stacy Loeb; Zhaoyong Feng; Sumit Isharwal; Patricia Landis; Debra J Elliot; Robert Veltri; Jonathan I Epstein; Alan W Partin; H Ballentine Carter; Bruce Trock; Lori J Sokoll
Journal:  J Urol       Date:  2012-08-15       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.